| Stage of disease | IV |
| Date of Draw | 2024/7/2 |
| Lab Tests | CBC: 2-Jul-2024: RBC: 3.6*1012/L; HGB: 128 g/L; PLT: 234*109/L; WBC: 7.7*109/L; NEU: 74%; EOS: 1%; BAS: 1%; LYM: 24%; ESR: 60 mm/hour. Biochemistry: 2-Jul-2024: Total protein: 71 g/L; Total bilirubin: 20 μmol/L; Direct bilirubin: 9 μmol/L; ALAT: 41 u/L; ASAT: 44 u/L; Creatinine: 100 μmol/L; Urea: 5.1 mmol/L; Glucose: 4.8 mmol/L; Total cholesterol: 4.4 mmol/L |
| N (Node) | cN2 |
| Treatment of Concomitant Diseases | No |
| M (Metastasis) | cM1 |
| Date of diagnosis | 2024/6/26 |
| Drinking History | Non-drinker |
| Biomarkers | 26-Jun-2023: ER negative; PR negative; HER2 negative; Ki-67 60% |
| Race | Caucasian |
| Height, cm | |
| Treatment | Not treated |
| Processing | Single spin |
| Weight, kg | 68 |
| Concomitant Diseases | No |
| Pathology Report | Invasive carcinoma of no special type (NST) of the right breast, tumor size: 11.5 cm x 9.8 cm x 10.0 cm. Mts: axillary lymph nodes; Paraaortic lymph nodes, supradiaphragmatic lymph nodes. |
| Grade | G3 |
| COVID-19 Vaccination | Vaccinated: Moderna, 2 doses |
| Clinical diagnosis | TNBC: Invasive carcinoma of no special type (NST) |
| T (Tumor) | cT4 |
| HIV, HBV, HCV, RPR | Negative |
| Location Country | Ukraine |
| Smoking History | Non-smoker |
| Cancer History and Relapses | No |
